Treatment of anxiety with ketazolam in elderly patients. In a multicenter, double-blind trial, 63 elderly patients who had experienced a generalized anxiety disorder for at least one month were randomly assigned to receive 15 mg of ketazolam (n = 31) or placebo (n = 32) daily for 15 days. At the end of this period, if their total scores on the Hamilton Anxiety Rating Scale had decreased by at least 25%, treatment was continued unchanged for a further 15 days. Patients who did not respond to treatment were given an additional 15 mg of ketazolam daily. During the initial 15 days, 83% of the ketazolam-treated patients and 43% of the placebo patients responded to treatment (P < 0.01). During the second 15-day period, the anxiety scores of the ketazolam-treated patients continued to decline
Low doses of ketazolam in anxiety: a double-blind, placebo-controlled study. A multicenter, double-blind, between-patient trial comparing two doses of ketazolam (15 and 30 mg) with placebo, each given once daily, in the evening, to 92 outpatients affected by generalized anxiety disorders for at least 1 month, was carried out. After 1-week washout period 47 patients were randomized to ketazolam 15 mg, and 45 to placebo for 15 days (first period). At the end of this period, if the patient experienced a decrease on the total Hamilton Anxiety Rating Scale (HAM-A) of at least 25% of basal value, the treatment was kept unchanged for a further 15 days, otherwise 15 mg of ketazolam were added to the previous treatment (second period). Anxiety was rated after 2 and 4 weeks with the Italian HAM
Comparison of the therapeutic effect, tolerance and safety of ketazolam and diazepam administered for six months to out-patients with chronic anxiety neurosis. Recently, it has been argued that benzodiazepines may not be safe or efficacious beyond 3 months continuous dosage. This study was designed to provide data regarding efficacy, safety, possible tolerance development, and possible withdrawal effects of administering ketazolam and diazepam for a 6-month period. Chronic anxiety patients were screened for participation according to specific inclusion and exclusion criteria. Of 139 patients, forty-four terminated prematurely for non-drug related reasons and are not included in the analysis. Of the ninety-five patients remaining, sixty-three were on ketazolam, and thirty-two on diazepam
Double-blind placebo-controlled efficacy study of ketazolam (U-28,774). The safety and efficacy of ketazolam (15 mg capsules) was compared to placebo in seventy-nine out-patients suffering from psychoneurotic anxiety, moderate or worse in severity. A flexible dosage range of 15-75 mg was used in this double-blind study lasting twenty-eight days. The average optimum therapeutic dose of ketazolam was 46-9 mg administered as a once-day dose at bedtime. Ketazolam was found to be significantly better than placebo in alleviating anxiety and its concomitant symptomatology as measured by the Hamilton Anxiety Rating Scale, three Physician's Global Impressions, two Patient's Global Impressions, and three Target Symptoms. Fifteen patients dropped from the placebo group before completion of the study
Ketazolam and diazepam in anxiety: a controlled study. Ketazolam (both in once-daily and three-times-daily dosing), diazepam, and placebo were compared for effectiveness in relieving anxious symptomatology in a clinical trial conducted with a total of 222 anxious, non-psychotic outpatients. Results indicated that improvement occurred early in treatment, that ketazolam was equally effective in both once-daily and three-times-daily dosing, and that ketazolam was similar in effect to diazepam. Ketazolam (both once-daily and three-times-daily) and diazepam were significantly (P < 0.05) better than placebo in alleviating symptoms of anxiety, as measured by the Hamilton Anxiety Scale, the Covi Anxiety Scale, and a physician-rated measure of global improvement.
Ketazolam compared to diazepam and placebo in the treatment of anxiety. Compared to placebo, ketazolam given once daily was more effective in alleviating the symptoms of anxiety than was diazepam given three times a day in this 28-day double-blind study in fifty-six out-patients. Ketazolam patients reported fewer, milder side-effects than diazepam patients. In particular, drowsiness was reported less than 8% as often during ketazolam treatment as during diazepam treatment.
Anxiolytic efficacy and safety of ketazolam compared with diazepam and placebo. A 28-day, double-blind study involving 56 outpatients ws initiated to compare the anxiolytic efficacy and safety of ketazolam once a day at bedtime (HS) with diazepam given three times a day (TID) and placebo HS or TID. Ketazolam HS was at least equivalent, and in some respects superior, to diazepam TID with fewer , less severe side effects. The superiority of ketazolam over placebo was demonstrated on all five instruments used to evaluate efficacy, three rated by the physician and two by the patient. The efficacy of ketazolam was significant at all three follow-up evaluations, whereas significant results for diazepam were achieved mainly at weeks 1 and 2, with little seen at week f. Fewer side effects were
Double-blind comparison of ketazolam, diazepam and placebo in once-a-day vs t.i.d. dosing. Comparison of ketazolam given once-a-day with diazepam given three times a day and placebo given either once or 3 times a day in 101 anxious outpatients showed ketazolam to be significantly better than placebo in alleviating the symptoms of anxiety and, on several measures of efficacy, better than diazepam as well. Significantly fewer patients on ketazolam dropped out of the study due to ineffective medication than on the other 3 treatments. The incidence of side effects was lowest in the ketazolam group. Of particular note, drowsiness was reported twice as often by diazepam patients as by ketazolam patients.
Pilot investigation of the quantitative EEG and clinical effects of ketazolam and the novel antiemetic nonabine in normal subjects. Nonabine is a chromenol structurally related to the cannabinoids which has shown antiemetic efficacy in clinical trials. Oral doses of 5, 10, and 15 mg were given to healthy volunteers in a crossover study with the benzodiazepine ketazolam, 30 and 45 mg. Ketazolam
Ketazolam treatment for spasticity: double-blind study of a new drug. A minor tranquilizer, ketazolam, was tested in a double-blind, randomized, crossover study of 50 patients for its effects in neurologic spasticity. The drug was compared with diazepam (widely accepted as an effective antispasticity agent) and a placebo. The patients with spasticity were almost all cases of multiple sclerosis (24) or stroke (24). Thirty-nine patients completed the study. There was not statistically significant superiority of either diazepam or ketazolam, but both relieved symptoms significantly better than the placebo, as measured clinically and by electromyographic recording of deep tendon reflexes. Ketazolam is a relatively safe and clinically effective antispasticity agent (especially for patients
Ketazolam once daily for spasticity: double-blind cross-over study. This double-blind cross-over study of 14 severely spastic inpatients with chronic multiple sclerosis reveals that once-daily doses of ketazolam, a new drug, are effective in reducing spasticity in a significant proportion of patients without significant side-effects. Added to the similar findings of an earlier double-blind controlled study of divided doses, the results suggest that this special feature of ketazolam provides a unique flexibility that may be exploited in individual cases.
Any pharmacological interventions. Interventions evaluated in the included studies were kava-kava (70mg); clobazam (10mg); diazepam (5mg-33mg), ketazolam (50mg-60mg) and lorazepam (1..
Ketazolam (Solatran) an open study of once-a-day treatment in ambulatory patients with anxiety. The efficacy of ketazolam (Solatran) in alleviating the symptoms of short-term reactive or neurotic anxiety in thirty-three patients was examined using a single 30 mg night-time dose in an open study. Patients were to receive treatment for up to 1 month and thereafter as necessary for several months
40 3–6 15-35 [30-100] anxiolytic Ketazolam Anxon 1980 . ketazolam, cloxazolam etc.), and other compounds not researched by Roche * Benzodiazepines developed more recently (e.g. remimazolam, QH-ii-066, Ro48-6791 etc.) * "Designer" benzodiazepines for which in vitro binding data is unavailable (e.g. flubromazolam, pyrazolam etc.)[49][50][51][52][53]While binding or activity data is available for most of these compounds also, the assay conditions vary between